Hybrid/Virtual/Decentralized Clinical Trials Market Outlook

Description

Throughout ISR’s many years of conducting market research in the drug development sphere, we have rarely – if ever – heard those in the industry speak about its capacity for rapid change. We get it. Change is hard. And it can certainly be intimidating, especially in an area like drug development when there is much at stake and many complexities to manage. Enter COVID-19. The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities. The hybrid model quickly became essential for allowing patients to continue with their trials amidst a global pandemic and the myriad health and logistical concerns that accompanied it.

We surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services. Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials. Furthermore, respondents do not seem to consider the hybrid trial model as a temporary solution to be discarded after the pandemic has subsided. A whopping 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now. These data are saying loud and clear that hybrid trials are here to stay.

"Hybrid/Virtual/Decentralized Clinical Trials Market Outlook"

Pharmaceutical Organizations:

  • Learn from survey-takers’ verbatim responses on “lessons learned” from conducting hybrid trials and which aspects of hybrid trials have worked well for them
  • Plan ahead for managing your hybrid trials by understanding which components are considered easier to manage in a hybrid trial vs. in a traditional trial model
  • Make more informed provider selections by knowing how industry peers select hybrid trial providers and how providers have performed for recent users
  • Discover in which areas related to hybrid trials companies are investing significant resources

Service Providers:

  • Understand the selection drivers most important to sponsors when choosing hybrid trial providers
  • Learn how users of hybrid trials view your company (and your competitors) along brand metrics of leadership, familiarity with hybrid trial offerings, proposal requests, reported use, and how providers performed compared to their expectations
  • Discover which technologies respondents believe need the most improvement to meet hybrid trial needs and read, in respondents’ own words, their unmet technology-related needs
  • Hybrid Trial Use and Experience
  • Provider Selection
  • Provider Perceptions
  • Future Predictions
  • Study Data

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.

"For Service Provider Leadership"

Hybrid Trial Use and Experience

Primary Section Takeaways
Terminology Used
Utilization of Virtual Components
Managing Trial Components: Hybrid vs. Traditional Models
Overall Hybrid Trial Experience
Lessons Learned
Aspects That Have Gone Well
Aspects That Have Been Frustrating
Potential Benefits to Patients
Potential Benefits to Sites
Potential Benefits to Sponsors/CROs
Primary Hybrid Trial Challenge
Technologies Needing Improvement

Provider Selection

Primary Section Takeaways
Selection Drivers for Hybrid Trial Providers
Trust in Providers’ Hybrid Trial Offerings
Sponsor Influence over Selection of Apps, Device, or Platforms when Monitoring is Outsourced
Departmental Influence over Selection of Apps, Device, or Platforms when Monitoring is In-house

Provider Perceptions

Primary Section Takeaways
Unaided Hybrid Trial Provider Leadership
Hybrid Trial Provider Metrics
Hybrid Trial Provider Performance

Future Predictions

Primary Section Takeaways
Hybrid vs. Traditional Trial Use in Three Years
Areas of Investment
Hybrid vs. Traditional Trial Costs

Study Data

Terminology Used
Hybrid Trial Use
Utilization of Virtual Components
Managing Trial Components: Hybrid vs. Traditional Models
Overall Hybrid Trial Experience
Lessons Learned
Aspects That Have Gone Well
Aspects That Have Been Frustrating
Potential Benefits to Patients
Potential Benefits to Sites
Potential Benefits to Sponsors/CROs
Challenges of Hybrid Trials
Primary Hybrid Trial Challenge
Whether Clinical Technologies Meet Hybrid Trial Needs
Technologies Needing Improvement
Unmet Needs by Technology

eCOA
ePRO
Telehealth/video visit software
Wearable sensors/connected health devices
Patient-facing web portals

In-house vs. Outsourced Hybrid Trials
Sponsor Influence over Selection of Apps, Device, or Platforms when Monitoring is Outsourced
Departmental Influence over Selection of Apps, Device, or Platforms when Monitoring is In-house
Selection Drivers for Hybrid Trial Providers
Trust in Providers’ Hybrid Trial Offerings
Unaided Hybrid Trial Provider Leadership
Aided Hybrid Trial Provider Leadership
Familiarity with Providers’ Hybrid Trial Offerings
Hybrid Trial Proposal Requests
Use of Hybrid Trial Providers
Hybrid Trial Provider Performance
Provider Performance Rating Explanations

Covance
ERT
ICON
IQVIA
Medable
Medidata
Medpace
Oracle
Parexel
PPD
PRA Health Sciences
Premier Research
Science 37
Signant Health (including Virtrial)
Syneos
Thread
Veeva
Worldwide Clinical Trials

Hybrid vs. Traditional Trial Costs
Areas of Investment
Hybrid vs. Traditional Trial Use in Three Years

Demographics

Company Type
Company Size
Office Location
Job Level
Decision-making Responsibility
Outsourcing Involvement by Phase
Involvement in Hybrid Trials
Number of Hybrid Trials

Additional information

License

, ,